Arcadia Biosciences (RKDA) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RKDA shares.
View RKDA analyst ratings or view top-rated stocks.

1 equities research analysts have issued 12-month price objectives for Arcadia Biosciences' shares. Their RKDA share price forecasts range from $10.00 to $20.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 349.1% from the stock's current price.
View analysts price targets for RKDA or view top-rated stocks among Wall Street analysts.

Arcadia Biosciences' stock was trading at $0.2710 at the beginning of 2023. Since then, RKDA stock has increased by 1,132.5% and is now trading at $3.34.
View the best growth stocks for 2023 here.

Arcadia Biosciences saw a decrease in short interest in August. As of August 31st, there was short interest totaling 600 shares, a decrease of 87.2% from the August 15th total of 4,700 shares. Based on an average daily trading volume, of 38,900 shares, the short-interest ratio is currently 0.0 days. Approximately 0.1% of the company's shares are sold short.
View Arcadia Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our RKDA earnings forecast.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) issued its earnings results on Thursday, August, 10th. The basic materials company reported ($2.64) earnings per share for the quarter, beating the consensus estimate of ($4.92) by $2.28. The basic materials company had revenue of $1.39 million for the quarter, compared to the consensus estimate of $1.43 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 69.76% and a negative net margin of 271.33%.

Shares of Arcadia Biosciences reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Arcadia Biosciences updated its second quarter 2023 earnings guidance on Thursday, July, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.30 million-$1.50 million, compared to the consensus revenue estimate of $1.82 million.

1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RKDA stock can currently be purchased for approximately $3.34.

Arcadia Biosciences (NASDAQ:RKDA) has a market capitalization of $3.71 million and generates $9.96 million in revenue each year. The basic materials company earns $-15,380,000.00 in net income (profit) each year or ($21.36) on an earnings per share basis.

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The official website for the company is www.arcadiabio.com. The basic materials company can be reached via phone at (530) 756-7077, via email at ir@arcadiabio.com, or via fax at 530-756-7027.